U.S. markets open in 3 hours 16 minutes

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.34+0.65 (+3.89%)
At close: 04:00PM EDT
17.34 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close16.69
Bid0.00 x 1100
Ask0.00 x 800
Day's Range16.87 - 17.55
52 Week Range13.05 - 35.93
Avg. Volume233,071
Market Cap854.978M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-2.26
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for REPL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Replimune Group, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • Motley Fool

    Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

    U.S. stock markets have been exceedingly volatile in 2022. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- are a prime example. Perhaps most interestingly, the Baker brothers bought large chunks of small-cap healthcare stocks Affimed (NASDAQ: AFMD), Cerus Corporation (NASDAQ: CERS), and Replimune Group (NASDAQ: REPL) in the most recent quarter.

  • Simply Wall St.

    Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • GlobeNewswire

    Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

    Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 First 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma; data snapshot from these patients with six-month follow-up expected to be released in Q4 2022 RP2/3 update to be provided by year end,